Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic acid and ezetimibe FDC in patients on maximally tolerated statins
NCT03337308Phase 3Completed
- Sponsor
- Esperion Therapeutics
- Start
- Oct 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bempedoic acid in hyperlipidemia, sponsored by Esperion Therapeutics. Started Oct 2017; status: completed.
02
Drugs
bempedoic acid
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT03337308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03337308.